Development plan

Autoimmune disease spans 100+ conditions and affects over 300 million people; more than 20 million cases are rare. The field is moving from broad immunosuppression toward precision immune reset. EA2-targeted therapeutics align with this shift by modulating early T- and B-cell activation to provide broader, longer-lasting control with potential for better safety profile.

Strategy: begin in rare indications and refractory populations with strong biology and efficient proof-of-concept designs; work with specialized partners in medicinal chemistry, screening, DMPK, and translational biology.

High-level timeline

  • Discovery (0–12 m): hit validation, SAR, early PK/PD.
  • Lead optimization (12–24 m): potency, selectivity, ADME; IP filings.
  • Pre-IND (24–36 m): CMC planning, GLP tox design, IND preparation with partners.

Near-term objectives (next 12 months)

  • Prioritize chemotypes; confirm EA2 engagement.
  • Advance SAR; improve potency and selectivity.
  • Early PK/PD and in-vitro DMPK.
  • Strengthen IP (composition of matter; MoA).

What we’re seeking

  • Seed/bridge capital to progress hit → lead.
  • Medicinal chemistry collaboration.
  • Screening/CRO partners and assay support.
  • KOL input on indication fit & endpoints.
Contact us